Damora Therapeutics, Inc.
Cash Flow Statement
| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-32.0M | $-31.2M | $-27.8M | $-200.7M | $-3.1M | $-3.4M | $-2.5M | $-6.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $5.0K | $6.0K | $5.0K | $5.0K | $6.0K | $6.0K | $5.0K | $5.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.5M | $6.1M | $3.1M | $483.0K | $164.0K | $172.0K | $179.0K | $308.0K |
| Net Cash from Operating Activities | $-17.2M | $-21.9M | $-20.6M | $566.0K | $-2.6M | $-2.2M | $-2.4M | $-4.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $5.1M | $29.5M | $295.9M | — | — | — | — | — |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |